1. In Vivo
  2. >>Market Access

Podcast: A Man On Fire Fueled By A Mission To Find A Drug For Every Disease

 
• By David Wild

David Fajgenbaum has become a "man on fire," determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts have been recognized by former President Bill Clinton, spoke with In Vivo about his own patient journey with a disease with no approved treatment and about the Every Cure Foundation, a non-profit he co-founded to fulfill his ambitions.   

In Vivo Podcast
• Source: Shutterstock

David Fajgenbaum is on a mission to repurpose drugs for the 9,000 diseases with no approved treatments. Fajgenbaum's journey started as a patient with idiopathic multicentric Castelman disease, an illness that he nearly succumbed to five times and for which he found a treatment. In September 2022, Fajgenbaum co-founded the Every Cure Foundation, a non-profit organization that identifies and tests generic medicines for novel indications. 

Open

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

UK Must Put Adoption On A Par With Innovation, AZ Tells BioWales Forum

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Biotech Leaders Ponder Trump’s Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.